Denali Therapeutics Inc. Derivative Asset
Denali Therapeutics Inc. (DNLI) had Derivative Asset of $7.00 thousand as of 2021-06-30, per its 10-Q filed 2021-08-04.
Discontinued › Balance Sheet › Assets
us-gaap:DerivativeAssets · last filed 2022-02-28
- 2021-06-30: Derivative Asset $7.00K.
- 2021-03-31: Derivative Asset $45.00K.
- 2020-12-31: Derivative Asset $185.00K.
- 2020-09-30: Derivative Asset $109.00K.
| Period end | Derivative Asset | Derivative Asset as first filed |
|---|---|---|
| 2021-06-30 | $7.00K 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $45.00K 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $185.00K 10-K · filed 2022-02-28 | |
| 2020-09-30 | $109.00K 10-Q · filed 2020-11-05 | |
| 2019-12-31 | $85.00K 10-K · filed 2021-02-26 | |
| 2019-09-30 | $14.00K 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $15.68K 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $25.68K 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $14.00K 10-K · filed 2020-02-27 | $13.67K 10-K · filed 2019-03-12 |
| 2018-09-30 | $3.67K 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |